Novel Oral Anticoagulants

A New Practical Guide From the European Heart Rhythm Association

Samuel Z. Goldhaber, MD


November 12, 2013

This feature requires the newest version of Flash. You can download it here.

Hello. This is Dr. Sam Goldhaber for the Clotblog at, speaking to you from Brigham and Women's Hospital and Harvard Medical School to tell you about a new practical guide on the novel oral anticoagulants (NOACs) for atrial fibrillation, from the European Heart Rhythm Association.[1]

I recently found out about this newly published information. The guide contains a long version and an executive summary. Both are worthwhile. The long guide explains how to convert a warfarin anticoagulation service to a NOAC anticoagulation service. It also discusses drug-drug interactions, and there are quite a few cardiac drugs that one should be careful of when prescribing NOACs. Tips are given on how to determine compliance with NOACs and how to dose NOACs in the presence of chronic kidney disease. There is also practical information on how to deal with major bleeding complications from the NOACs and how to deal with planned surgery or emergency surgery for patients who are taking NOACs. There is particular emphasis on cardioverting patients on NOACs and doing ablation of atrial fibrillation as well.

On the Clotblog, I have listed both the extended document and the executive summary for your reading convenience. I found them very helpful. This is Dr. Sam Goldhaber, signing off for the Clotblog.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: